of customers who previously used Radar 1.0 have ordered Radar SD since launch. Additionally, 34% of RADAR-ST orders received include additional NEO tests. All test results to date have been delivered faster than our published turnaround times. RADAR-ST represents a very import

Jul 28, 2026 / receipt

Operational Excellence: since launch all tests were resulted significantly faster than our published TAT.

ir_statement / Sep 17, 2026 / receipt

Portfolio Expansion Opportunity: 34% of RaDaR ST orders have included additional NEO portfolio testing.

ir_statement / Sep 17, 2026 / receipt

Specialized salesforce

ir_statement / Sep 17, 2026 / receipt

~75% of community oncologists new to NEO in 2025 ordered 5+ tests

ir_statement / Sep 17, 2026 / receipt

NEO sales headcount

ir_statement / Sep 17, 2026 / receipt

Decline in margin in Q2 2025 driven by Pathline Acquisition

ir_statement / Sep 17, 2026 / receipt

Gross Margin Expected to Increase by 100 bps In 2026

ir_statement / Sep 17, 2026 / receipt

Gross Margin improvement initiatives including lab automation and AUP increase

ir_statement / Sep 17, 2026 / receipt

Adj. EBITDA up +27% YoY with +60 bps margin expansion

ir_statement / Sep 17, 2026 / receipt

OpEx down (2%) YoY to $99M, primarily driven by non recurrence of one-time items last year and expense management

ir_statement / Sep 17, 2026 / receipt

Margin expansion of approximately100 bps YoY

ir_statement / Sep 17, 2026 / receipt

Sales force expansion

ir_statement / Sep 17, 2026 / receipt